Nuclear medicine technologists and investigators who perform imaging procedures in
clinical trials often have not received training on clinical research regulations, such as Title …

We are facing a potential paradigm shift, moving from the traditional gauge of drug efficacy
based on tumor shrinkage, which can take months to manifest on a CT scan, to a biomarker …

This special contribution provides insight into the role that standard operating procedures
(SOPs) play in an imaging department and their value in building a high-quality research …

Clinical trial design for nuclear medicine diagnostic imaging radiopharmaceuticals must
include a design for preclinical safety studies. These studies should establish that the …

This article is part of a series developed by the Clinical Trials Network of the Society of
Nuclear Medicine and Molecular Imaging to offer training and information for molecular …

Rationale and Objectives Participation in clinical research can be both highly rewarding and
logistically demanding. As highlighted by recent Food and Drug Administration guidance …

Molecular imaging is being hailed as the next great advance for imaging. Since molecular
imaging typically involves the use of specific imaging probes that are treated like drugs, they …

The process of diagnosing and treating disease is shifting from a single specialist interacting
with a patient to a multidisciplinary approach that retains a focus on the patient. The focus of …

Pharmaceutical companies typically perform prospective, multicenter phase 3 clinical
studies to support approval of a new imaging agent by the US Food and Drug Administration …

This special issue of the journal contains contributions from participants of the third La Jolla
meeting (The Magic Bullet: A Century Later). The goal of this meeting was twofold: to review …